Lv11
32 积分 2026-04-21 加入
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies
6小时前
已完结
Dysregulated CDKN2A-MDM2-p53 axis in B cell of systemic lupus erythematosus
3天前
已完结
Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
13天前
已完结
56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma
13天前
已完结
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
17天前
已完结
Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
21天前
已完结
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
22天前
已完结
Differential molecular mechanistic behavior of HDACs in cancer progression
1个月前
已完结
Targeting DNA methyltransferases for cancer therapy
1个月前
已完结
Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)
2个月前
已关闭
皖公网安备34019202002308
